Opus Genetics, Inc. (IRD) Stock Forecast Oct. 15, 2026
Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Opus Genetics, Inc. (IRD) stock forecast summary
Our AI ranks Opus Genetics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Opus Genetics, Inc. is a small-cap company with a market capitalization of $341M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For IRD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 30.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 26.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, IRD included.
Follow IRD freeIRD price chart and AI forecast
How IRD ranks among 5111 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Opus Genetics, Inc. (IRD) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | IRD | Rank |
|---|---|---|
| Market Cap | $341M | 60/60 |
| EPS | $-0.82 | – |
| Revenue/Share | $0.12 | – |
Profitability & Margins
| Metric | IRD | Rank |
|---|---|---|
| ROIC | -59.3% | 37/44 |
| Operating Margin | -513.5% | 34/37 |
| EBT Margin | -1091.8% | 42/44 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | IRD | Rank |
|---|---|---|
| Current Ratio | 12.19x | 11/56 |
| Interest Coverage | -58.6x | 32/35 |
| Working Capital | $85M | 50/56 |
Cash Flow
| Metric | IRD | Rank |
|---|---|---|
| Operating Cash Flow | -$41M | 37/56 |
Operational Efficiency
| Metric | IRD | Rank |
|---|---|---|
| Asset Turnover | 0.11x | 36/39 |
| Receivables Turnover | 9.5x | 6/36 |
| Fixed Assets Turnover | 57.3x | 12/41 |
| Days Sales Outstanding | 39 days | 31/36 |
Income Statement
| Metric | IRD | Rank |
|---|---|---|
| Total Revenue | $10M | 43/44 |
| Operating Income | -$51M | 28/48 |
| R&D Expense | $39M | 54/55 |
Dividend & Shareholder Information
| Metric | IRD | Rank |
|---|---|---|
| Shares Outstanding | 83M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $93M | |
| Cash & Short-term Investments | $89M | |
| Accounts Receivable | $1M | |
| Total Liabilities | $106M | |
| Short-term Debt | $6M |
IRD quarterly financials and insider trading
Opus Genetics, Inc. (IRD) industry peers
Companies classified under the same SEC industry code as Opus Genetics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| IRD Opus Genetics, Inc. | ▲ | $341M |
| LLY Eli Lilly & Co | ▶ | $1.14T |
| JNJ Johnson & Johnson | ▼ | $611.90B |
| ABBV Abbvie Inc. | ▶ | $500.75B |
| MRK Merck & Co., Inc. | ▶ | $363.59B |
| NVS Novartis Ag | ▼ | $280.27B |
| AZN Astrazeneca Plc | ▼ | $258.35B |
| ABT Abbott Laboratories | ▼ | $182.04B |
| NVO Novo Nordisk A S | ▼ | $169.41B |
| PFE Pfizer Inc | ▼ | $166.49B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▼ | $126.35B |
| BMY Bristol Myers Squibb Co | ▶ | $123.73B |
| SNY Sanofi | ▼ | $98.05B |
| GSK Gsk Plc | ▼ | $96.58B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $80.48B |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.45B |
| ONC Beone Medicines Ltd. | ▲ | $39.96B |
| RPRX Royalty Pharma Plc | ▲ | $33.92B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.32B |
| ZTS Zoetis Inc. | ▼ | $31.11B |
| TAK Takeda Pharmaceutical Co Ltd | ▶ | $30.24B |
| ATHE Alterity Therapeutics Ltd | ▶ | $25.65B |
| ZLAB Zai Lab Ltd | ▶ | $25.26B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.28B |
| GMAB Genmab A/S | ▶ | $23.73B |
| UTHR United Therapeutics Corp | ▼ | $23.16B |
| INSM Insmed Inc | ▶ | $21.36B |
| VTRS Viatris Inc | ▶ | $20.03B |
| ASND Ascendis Pharma A/S | ▲ | $14.94B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.61B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $13.12B |
| CORT Corcept Therapeutics Inc | ▲ | $12.56B |
| SMMT Summit Therapeutics Inc. | ▶ | $12.07B |
| ELAN Elanco Animal Health Inc | ▼ | $11.27B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.85B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.64B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.63B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.82B |
| CYTK Cytokinetics Inc | ▲ | $8.82B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.47B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.26B |
| ABVX Abivax S.A. | ▼ | $7.26B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.10B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $6.93B |
| ALKS Alkermes Plc. | ▲ | $6.73B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.67B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.16B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.15B |
| BLTE Belite Bio, Inc | ▲ | $6.00B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.97B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.88B |
| BLRX Biolinerx Ltd. | ▶ | $5.43B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.19B |
| ERAS Erasca, Inc. | ▲ | $5.14B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $5.08B |
| TVTX Travere Therapeutics, Inc. | ▲ | $5.02B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.98B |
| COGT Cogent Biosciences, Inc. | ▶ | $4.88B |
| MANE Veradermics, Inc | ▲ | $4.74B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.18B |
Where IRD sits on the market map
Opus Genetics, Inc. (IRD) stock news
Loading...
Opus Genetics, Inc. (IRD) stock forecast FAQ
What is the Opus Genetics, Inc. (IRD) stock forecast?
Our AI ranks Opus Genetics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Opus Genetics, Inc. stock predictions?
For IRD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 30.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 26.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Opus Genetics, Inc. forecasts updated?
Opus Genetics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Which companies are Opus Genetics, Inc.'s industry peers?
60 issuers in our coverage, IRD included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.